Meeting Banner
Abstract #2776

Reliability of DCE pharmacokinetic parameter values for quantitative longitudinal assessment of brain tumors

Moran Artzi1, Gilad Liberman2,3, Deborah Blumenthal4, Orna Aizenstein1, and Dafna Ben Bashat1,5

1Functional Brain Center, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, 2Functional Brain Centerasky Medical Cente, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, 3Department of Chemical Physics, Weizmann Institute, Rehovot, Israel, 4Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, 5Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel-Aviv, Israel

DCE-MRI parameters have been shown to be useful for therapy response assessment in patient with glioblastoma, yet the estimated parameters may show high variation in their values. This study investigated the reliability of DCE parameters for quantitative longitudinal assessment of brain tumors. 14% standard-deviation in the WM and 12% in the GM, were detected for vp in healthy subjects(n=27). Results from six patients showed mean differences of 3.2%/9.7% in vp for WM/GM in the hemisphere contralateral to the lesion, comparing two longitudinal scans. Parametric-response-maps calculated within lesion areas based on the threshold values from the healthy controls supported radiological assessment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here